Pharmacokinetics and suggested oral dosing regimen of cisapride: a study in healthy cats.
The disposition of cisapride in seven healthy cats was determined following administration of either a single oral (2 mg/kg body weight) or intravenous (i.v.) (1 mg/kg body weight) dose. Cats were studied using a random crossover design. After administration of the oral capsule, maximum plasma drug concentration (Cmax) +/- standard deviation (SD) was 73.32 +/- 16.59 ng/ml, and bioavailability +/- SD was 29.0 +/- 22.6%. Following i.v. administration, extrapolated peak cisapride concentration (C0) +/- SD was 421.30 +/- 155.37 ng/ml, and clearance +/- SD was 15 +/- 0.67 ml/kg per minute. Elimination half-life (T1/2) was similar for both routes of administration (T1/2(oral) +/- SD was 5.27 +/- 3.16 hr, T1/2(i.v.) +/- SD was 5.19 +/- 3.77 hr). Adverse effects were not observed. Based on these results, a dose of 1 mg/kg body weight per os (PO) every eight hours or 1.5 mg/kg body weight every 12 hours is expected to result in plasma drug concentrations within the therapeutic ranges established for humans.
LeGrange
S N
SN
Department of Small Animal Medicine, College of Veterinary Medicine, Texas A&M University, College Station 77843, USA.
Boothe
D M
DM
Herndon
S
S
Willard
M D
MD
D000284:Administration, Oral; D000469:Alkaline Phosphatase / Q000097:blood; D000818:Animals; D019540:Area Under Curve; D001682:Biological Availability; D001772:Blood Cell Count / Q000662:veterinary; D001786:Blood Glucose / Q000032:analysis; D001806:Blood Urea Nitrogen; D001835:Body Weight / Q000502:physiology; D002415:Cats / Q000097:blood / Q000378:metabolism* / Q000502:physiology; D020117:Cisapride; D018592:Cross-Over Studies; D004305:Dose-Response Relationship, Drug; D006207:Half-Life; D007275:Injections, Intravenous / Q000662:veterinary; D016014:Linear Models; D008297:Male; D008954:Models, Biological; D010880:Piperidines / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology; D012702:Serotonin Antagonists / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology; D012964:Sodium / Q000097:blood; D013047:Specific Pathogen-Free Organisms; D013997:Time Factors
D001786:Blood Glucose; D010880:Piperidines; D012702:Serotonin Antagonists; D012964:Sodium; D000469:Alkaline Phosphatase; D020117:Cisapride